Liquidia stock sets November 10 date for Q3 results

Liquidia Corporation will report its third-quarter 2026 financial results on Tuesday, November 10, the company said in an announcement carried by Yahoo Finance. Management plans to provide a corporate update during a webcast at 8:30 a.m. Eastern Time.

Liquidia stock traded at 37.71 euros on Lang & Schwarz at 22:30 CET on Tuesday, November 3, 2026. The scheduled webcast will be available through the company's investor-relations website, and a replay is planned to remain available for one year.

Focus remains on respiratory medicines

Liquidia develops and commercializes therapies for pulmonary hypertension and related conditions. Its commercial portfolio includes Yutrepia, an inhaled treprostinil powder approved for pulmonary arterial hypertension.

The company is also advancing L606, an extended-release treprostinil formulation intended for twice-daily use with a next-generation nebulizer. The program targets pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease.

Liquidia is developing Yutrepia for Raynaud's phenomenon associated with systemic sclerosis and is pursuing additional applications of its PRINT technology. The November 10 update is expected to give investors a fresh view of commercial execution and development priorities.

Investors can follow the real-time quote of Liquidia stock for the latest trading reference.

US equities trade within the broader context of the S&P 500.

More news and analyses are available on Liquidia stock.